Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. Its profile of action most closely resembles that of metoprolol which differs only in that it has some membrane stabilising activity. Atenolol has been well studied and is effective in the treatment of hypertension and in the prophylactic management of angina. Its narrow dose response range obviates the need for highly individualised dose titration. In patients with angina its long duration of beta-blocking activity allows once daily dosage, whereas other beta-blockers, unless in sustained release dosage forms, need to be given in divided doses. Other beta-blockers can be given once daily in hypertension, but at presnt the evidence for effective control with a once daily regimen is more convincing with atenolol. Further studies are need to clarify any important differences in blood pressure control between the various beta-blocking drugs, both in conventional or sustained release dosage forms. As with metoprolol, atenolol is preferable to non-selective beta-blockers in patients with asthma or diabetes mellitus. Atenolol has been well tolerated in most patients, its profile of adverse reactions generally resembling that of other beta-blocking drugs, although its low lipid solubility and limited penetration into the brain results in a lower incidence of central nervous system effects than seen with propranolol. Atenolol is eliminated virtually entirely as unchanged drug in the urine and dosage needs to be reduced in patients with moderate to severely impaired renal function (glomerular filtration rate less than 30 ml/min). There is no need for modification of dosage of atenolol in liver disease.
 ...
PMID:Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. 3 96

The antihypertensive effect of atenolol, a new beta-1-receptor blocking agent, was studied in a double-blind trial in which 45 patients with essential hypertension were randomly assigned to placebo or atenolol treatment. Atenolol caused a statistically significant and clinically relevant reduction of blood pressure. The optimum daily dose for moderately severe hypertension was considered to be 200 mg. Several irrelevant side effects were collected by the use of a check list, but there was no difference in the number of complaints during placebo and active treatment. Atenolol has a useful antihypertensive effect and, at least theoretically, has advantages over other beta-adrenergic blocking agents.
 ...
PMID:Controlled study of atenolol in treatment of hypertension. 23 10

A double-blind crossover trial was completed in 15 patients with moderate hypertension and the effects of propranolol (Inderal) 80 mg twice a day and atenolol (Tenormin) 100 mg twice a day were assessed on blood pressure, pulse rate and plasma renin activity (PRA), while patients were maintained on 1 cyclopenthiazide tablet (Navidrex K) per day. Both agents caused a significant reduction in blood pressure and pulse rate with patients at rest and during exercise. Plasma renin activity was significantly reduced by both agents in subjects with normal and high renin levels (with PRA 2-8 ng/ml/h and greater than 8 ng/ml/h respectively). Blood pressure responses could not be correlated with renin status or reduction in pulse rate. No adverse effects were attributable to either of the two beta-adrenergic blocking agents and we concluded that a beta1-selective agent, which has the advantage of not aggravating bronchospasm, can replace the non-selective propranolol.
 ...
PMID:Effects of propranolol and atenolol on blood pressure and plasma renin activity in patients with moderate hypertension. 34 73

The antihypertensive effect of atenolol, a new beta 1 receptor blocking agent, was studied in a double blind non cross-over trial in 40 patients (pts) affected by mild to moderately severe essential hypertension with normal plasma renin activity. After a run-in period (15 days) of placebo treatment pts were assigned to two groups. The first (group A) continued placebo treatment for 30 days, the second (Group B) were given atenolol (ICI 66082) 100 mg daily for 30 days also. Atenolol significantly reduced systolic and diastolic blood pressure in recumbent and standing position and heart rate at rest. No significantly changes of the same parameters were observed in group A. Body weight and plasma renin activity was unchanged in both groups. Atenolol treatment never was discharged in order to side effects. These results seem to suggest that atenolol can be an useful drug in the treatment of systemic blood hypertension.
 ...
PMID:[Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)]. 35 98

During the last four years we have used a new cardioselective beta-adrenergic blocking substance, ICI 66.082 (atenolol or Tenormin), alone or in combination with other drugs for treatment of hypertension in a total of 104 patients, including 15 with a chronic obstructive lung disease. Fifty-one patients started treatment with atenolol because of side-effects--especially from the central nervous system--during previous treatment with non-selective beta-blockers, mostly propranolol (Inderal). Mean duration of treatment was 16 months (range 8--36) and mean dosage 163 mg/day. In 18 patients treatment with Tenormin was withdrawn, but only in 10 of them could this be referred to side-effects. Of the 51 patients who complained of or showed side-effects from another beta-blocker, 80% were improved after changing to Tenormin. Of the patients with side-effects from the central nervous system, 73% improved, especially those who complained of nightmares, hallucinations, insomnia or mild depression.
 ...
PMID:Long-term clinical experience with atenolol--a new selective beta-1-blocker with few side-effects from the central nervous system. 36 88

In 15 patients with moderate to severe hypertension (WHO II--III) atenolol was evaluated against a thiazide diuretic (bendrofluazide) in a single blind crossover study. Systolic blood pressure values were lowered more efficiently by the diuretic, while diastolic pressure values were significantly better controlled by atenolol. Atenolol and bendrofluazide, by mere addition of the pressure effects of the single components, clearly afforded the best pressure control. Side effects of atenolol were frequent but mild, never causing major concern with the patients or a dropout from the study. Although the pressure response to atenolol was significantly better in the normal and high renin group of patients, there was no statistically significant correlation between the reduction in plasma renin and blood pressure induced by atenolol. In turn, the pressure response to the diuretic was significantly better in low renin than in normal and high renin patients.
 ...
PMID:[Atenelol and bendrofluazide in the treatment of medium and severe hypertension (preliminary report)]. 37 99

Twenty-seven patients with mild to moderate arterial hypertension were treated "double-blind" with either atenolol of oxprenolol. Placebo was given for four weeks before the beta-blocking drugs were administered. Atenolol was given in doses of either 50 mg twice a day, 100 mg twice a day or 100 mg once a day for periods of four weeks. Oxprenolol was given in doses of either 80 mg or 160 mg twice a day for the same duration. Patients were assessed at the end of each four-week period. The mean blood pressure and pulse rate did not vary significantly for the two different dose regimens at which each drug was administered. There was no statistical difference between the reduction of systolic blood pressure produced by the two drugs, but there was a significant difference in the reduction in diastolic blood pressure in favour of atenolol (P less than 0.05 supine; P less than 0.01 erect). A single, 100-mg daily dose of atenolol was just as effective as 50 mg or 100 mg twice a day. Similarly, an 80 mg twice a day dose of oxprenolol was just as effective as that of 160 mg twice a day. Side effects for each drug were not statistically different from those recorded with placebo.
 ...
PMID:Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison. 38 61

1. The effects of atenolol on diurnal blood pressure control, heart rate and plasma catecholamines were studied in nine hypertensives, six of whom also received diuretics. The patients completed a double-blind trial in which the effects of once and twice daily administration of atenolol were compared with placebo. 2. Atenolol (100 mg) given once a day produced significant reduction in diurnal blood pressures recorded at home but the effect was slightly less than either 50 mg given twice a day or 200 mg once a day. 3. Effects on heart rate and blood pressure were seen within 36 hours of the first dose, and were near maximal at 72 hours. After cessation of the drug, mean resting heart rate increased gradually and reached pre-treatment levels five days later, suggesting strong tissue binding of atenolol. Blood pressure increased more slowly over 8--10 days. 4. Plasma noradrenaline levels were increased at rest with atenolol. This argues strongly against the antihypertensive effect of atenolol being due to a reduction of sympathetic nerve activity. 5. Once daily administration of atenolol in this group of patients with mild hypertension produced satisfactory diurnal blood pressure control and beta blockade without "rebound" hypertension on cessation of therapy.
 ...
PMID:Home blood pressure monitoring and changes in plasma catecholamines during once or twice daily treatment with atenolol in patients with mild hypertension. 38 23

The effects on arterial pressure of saralasin and short-term (seven days) administration of the cardioselective beta-blocker atenolol were compared in 21 patients with various forms of hypertension. During saralasin administration mean arterial pressure (MAP) decreased by 8.8 +/- 2.1 per cent. Atenolol administration was associated with a MAP fall of 23.6 +/- 2.9 per cent. The change in MAP induced by atenolol was higher than that produced by saralasin (P less than 0.001) and no significant correlation (r = 0.40, P greater than 0.05) between their respective effects was found. These results suggest that the antihypertensive action of atenolol is not related to pre-treatment activity of the renin-angiotensin system as estimated by the hypotensive effect of saralasin. Other mechanisms should be sought in order to explain the effectiveness of this betablocker in hypertensive patients.
 ...
PMID:The renin-angiotensin system and the antihypertensive effect of atenolol in man. 52 65

Arterial pressure was continuously recorded for 24--48 h in 3 normotensive subjects and in 60 hypertensive patients. The greatest variations occurred in those with labile, mild or moderate hypertension compared to those with severe hypertension or normal blood pressure. Atenolol (100-200 mg) administered once or twice daily produced a significant reduction of arterial pressure and a smaller response to the cold pressor test, hand grip and step test in patients with established hypertension, but little change in those with labile hypertension. The evening dose was not followed by a decrease in pressure greater than that observed without treatment, but determined a smaller rise on awaking.
 ...
PMID:Circadian variations of blood pressure in patients with different degrees of hypertension. Changes induced by hypotensive treatment. 61 45


1 2 3 4 5 6 7 8 9 10 Next >>